Search Result

Isoforms Recommended:	PKCε

Results for "

PKC-ε

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PKC (19) Apoptosis (5) Autophagy (1) CaMK (1) Caspase (1) Lipoxygenase (1) Phosphatase (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (11) Neurological Disease (7)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Targets Recommended: PKC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122858A

PKCiota-IN-2 formic	PKC	Cancer
PKCiota-IN-2 formic is a potent PKCiota (PKC-ι) inhibitor with an IC₅₀ of 2.8 nM. PKCiota-IN-2 formic also inhibits *PKC-α* and *PKC-ε* with IC₅₀s of 71 nM and 350 nM, respectively .

HY-P10085

PKC-ε translocation inhibitor peptide	PKC	Inflammation/Immunology
PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .

HY-P5437

PKCε (85-92)	PKC	Others
PKCε (85-92) is a biological active peptide. (This peptide is the e-PKC specific activator, it also activates MARCKS phosphorylation in wild type cells, and has no effect on MARCKS phosphorylation in the cells derived from knockout mice.)

HY-P5888

PKCε inhibitor peptide,myristoylated Myr‐PKCɛ-	PKC	Inflammation/Immunology
PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated *PKC?* peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .

HY-122858

PKCiota-IN-2	PKC	Cancer
PKCiota-IN-2 (Compound 49) is a potent PKCiota (PKC-ι) inhibitor with an IC₅₀ of 2.8 nM. PKCiota-IN-2 also inhibits *PKC-α* and *PKC-ε* with IC₅₀s of 71 nM and 350 nM, respectively .

HY-122857

PKCiota-IN-1	PKC	Cancer
PKCiota-IN-1 (compound 51) is a potent PKCiota (PKC-ι) inhibitor with an IC₅₀ of 2.7 nM. PKCiota-IN-1 also inhibits *PKC-α* and *PKC-ε* with IC₅₀s of 45 nM and 450 nM, respectively .

HY-B0719

Ingenol Mebutate 1 Publications Verification Ingenol 3-angelate; PEP005	PKC	Inflammation/Immunology Cancer
Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent *PKC* modulator, with K_is of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.

HY-129624A

Bisindolylmaleimide VIII acetate Ro 31-7549 acetate; Bis VIII acetate	PKC Apoptosis	Inflammation/Immunology Cancer
Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC₅₀ of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC₅₀s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-β_I, PKC-β_II, PKC-γ, PKC-ε, respectively . Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases .

HY-P0154

Epsilon-V1-2 3 Publications Verification ε-V1-2; EAVSLKPT
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective *PKCε* inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC .

HY-108599A

DCPLA-ME 1 Publications Verification DCPLA methyl ester	PKC	Neurological Disease
DCPLA-ME, the methyl ester form of DCPLA, is a potent *PKCε* activator for use in the treatment of neurodegenerative diseases .

HY-10342

Enzastaurin 5+ Cited Publications LY317615	PKC Autophagy Apoptosis	Cancer
Enzastaurin (LY317615) is a potent and selective PKCβ inhibitor with an IC₅₀ of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε .

HY-117610A

Bisindolylmaleimide XI hydrochloride 2 Publications Verification Ro 32-0432; Ro 31-8830 hydrochloride	PKC	Inflammation/Immunology
Bisindolylmaleimide XI hydrochloride (Ro 32-0432) is a potent, selective and orally active *PKC* inhibitor with IC₅₀s of 9 nM, 28 nM, 31 nM, 37 nM, and 108 nM for PKCα, PKCβI, PKCβII, PKCγ, and *PKCε*, respectively .

HY-10343

Sotrastaurin Maximum Cited Publications 17 Publications Verification AEB071	PKC	Inflammation/Immunology Cancer
Sotrastaurin (AEB071) is a potent and orally-active pan-PKC inhibitor, with K_is of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively .

HY-16903

PKC-IN-1	PKC	Inflammation/Immunology
PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional *PKC* enzymes with K_is of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC₅₀s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.

HY-N0551

Wedelolactone 10+ Cited Publications	Caspase Lipoxygenase Apoptosis	Inflammation/Immunology Cancer
Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC₅₀ of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer .

HY-108599

DCP-LA 2 Publications Verification FR236924	PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates *PKCε*. DCP-LA activates Ca( ²⁺)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .

HY-13335

PKCβ inhibitor 1	PKC Apoptosis	Cancer
PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC₅₀s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε) .

HY-13866

Ro 31-8220 mesylate 10+ Cited Publications Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate	PKC	Cardiovascular Disease Neurological Disease Cancer
Ro 31-8220 mesylate is a potent *PKC* inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC₅₀s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.

HY-13866A

Ro 31-8220 Bisindolylmaleimide IX	PKC	Cardiovascular Disease Neurological Disease
Ro 31-8220 is a potent *PKC* inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC₅₀s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.

HY-108601A

(S)-Ro 32-0432	PKC	Neurological Disease Inflammation/Immunology
(S)-Ro 32-0432 is a potent, selective, ATP-competitive and orally active *PKC* inhibitor. The IC₅₀ values of (S)-Ro 32-0432 for PKCα, PKCβI, PKCβII, PKCγ and *PKCε* are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research .

HY-108601

(S)-Ro 32-0432 free base	PKC	Inflammation/Immunology
(S)-Ro 32-0432 free base is a potent, selective, ATP-competitive and orally active *PKC* inhibitor. The IC₅₀ values of (S)-Ro 32-0432 free base for PKCα, PKCβI, PKCβII, PKCγ and *PKCε* are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 free base is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 free base prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research .

HY-149489

JH-131e-153	Others	Neurological Disease
JH-131e-153, a diacylglycerol (DAG)-lactone, is a small molecule activator of Munc13-1, targeting the C1 domain. The activation sequence of JH-131e-153 on Munc13-1 is WT>I590≈R592A≈W588A. The C1 domain of Munc13-1 and protein kinase C (PKC) are homologous in sequence and structure. The activation sequence of JH-131e-153 on Munc13-1 and PKC was PKCα>Munc13-1>PKCε. JH-131e-153 regulates neuronal processes through Munc13-1 and can be further used in the study of neurodegenerative diseases .

Protein Kinase C Peptide Substrate PKCε; PRKCE ; Peptide Epsilon	Peptides	Neurological Disease Inflammation/Immunology Endocrinology
Protein Kinase C Peptide Substrate is targeted to a specific cellular compartment in a manner dependent on second messengers and on specific adapter proteins in response to extracellular signals that activate G-protein-coupled receptors, tyrosine kinase receptors, or tyrosine kinase-coupled receptors. Protein Kinase C Peptide Substrate then regulates various physiological functions including the activation of nervous, endocrine, exocrine, inflammatory, and immune systems .

PKC-ε translocation inhibitor peptide	PKC	Inflammation/Immunology
PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .

PKCε Inhibitor Scramble Peptide	Peptides	Others
PKCε Inhibitor Scramble Peptide is a scrambled peptide with identical amino acid composition to PKCε inhibitor peptide.

PKCε (85-92)	PKC	Others
PKCε (85-92) is a biological active peptide. (This peptide is the e-PKC specific activator, it also activates MARCKS phosphorylation in wild type cells, and has no effect on MARCKS phosphorylation in the cells derived from knockout mice.)

PKCε inhibitor peptide,myristoylated Myr‐PKCɛ-	PKC	Inflammation/Immunology
PKCε inhibitor peptide,myristoylated (Myr‐PKC?-) is a cell permeable myristic acid conjugated *PKC?* peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .

Ingenol Mebutate 1 Publications Verification Ingenol 3-angelate; PEP005	Structural Classification Classification of Application Fields Terpenoids Euphorbia peplus Linn. Diterpenoids Euphorbiaceae Plants Inflammation/Immunology Disease Research Fields	PKC
Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent *PKC* modulator, with K_is of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.

Wedelolactone 10+ Cited Publications	Structural Classification Classification of Application Fields Alysicarpus ovalifolius (Schumacher) J. Leonard Phenols Polyphenols Plants Compositae Inflammation/Immunology Disease Research Fields	Caspase Lipoxygenase Apoptosis
Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC₅₀ of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer .

PKC epsilon Antibody	WB, ICC, IHC-P, FC	Human, Mouse, Rat
PKC epsilon Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 84 kDa, targeting to PKC epsilon. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

PKC-ε

Inhibitors & Agonists

Peptides

NaturalProducts

Antibodies

Natural
Products